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Abstract
Objective: To establish a link between hypercholesterolemia and myocardial dysfunction.
Background: Heart failure is a complex disease involving changes in systolic and diastolic function.
Newer echocardiographic imaging modalities may be able to detect discreet changes in myocardial
function associated with hypercholesterolemia. Therefore we sought to establish a link between
hypercholesterolemia and myocardial dysfunction with tissue Doppler imaging (TDI).
Methods: Twenty-seven rabbits were studied: 7 were fed normal chow (group 1) and 20 a high
cholesterol diet (10 with ezetimibe, 1 mg/kg/day; group 2 and 10 without, group 3).
Echocardiographic images were obtained under general anesthesia. Serum cholesterol levels were
obtained at baseline, 3 and 6 months and myocardial cholesterol levels measured following
euthanasia.
Results: Doppler measurements, including E/A, E'/A' and S' were significantly lower in group 3
compared to both groups 1 and 2 but no significant differences were noted in chamber sizes or
ejection fraction among the groups. Average serum cholesterol was higher in group 3 compared
to groups 1 and 2 respectively (495 ± 305 mg/dl vs. 114 ± 95 mg/dl and 87 ± 37 mg/dl; p < 0.01).
Myocardial cholesterol content was also higher in group 3 compared to group 2 (0.10 ± 0.04 vs.
0.06 mg/dl ± 0.02; p = 0.05). There was significant correlation between S', E'/A', E/E' and serum
cholesterol (r2 = 0.17 p = 0.04, r2 = 0.37 p = 0.001 and r2 = 0.24 p = 0.01).
Conclusion: Cholesterol load in the serum and myocardium was significantly associated with
decreased systolic and diastolic function by TDI. Moreover, lipid lowering was protective.
Background
There are over five million cases of heart failure cases in
the United States causing an estimated death rate of over
a quarter of a million per year [1]. This complex condition
encompasses both systolic and diastolic dysfunction with
varying overlap between them [2]. Hypercholesterolemia
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is a well established risk factor for coronary artery disease
[3] and is related to endothelial dysfunction at both the
macro and microvascular level [4]. Furthermore, decreas-
ing serum cholesterol levels with exercise, diet and medi-
cations has been associated in numerous studies with
improved outcome [5]. But, the relationship of choles-
terol and direct myocardial function has not yet been
established. There have been several studies that have par-
adoxically demonstrated that hypercholesterolemia actu-
ally has a positive effect in patients with heart failure [6].
Furthermore, several studies that have attempted to
improve outcomes with cholesterol lowering medications
in patients with heart failure have shown either neutral or
negative results [7]. Several theories have been proposed
to explain these findings, but none have been accepted by
the medical community nor thoroughly investigated [8].
In order to elucidate this we tested the hypothesis that
cholesterol affects myocardial function. We sought to cor-
relate serum and myocardial cholesterol levels with
advanced echocardiographic parameters.
Echocardiography is a well-established clinical method
used to evaluate patients with heart failure [9]. Recently,
tissue Doppler imaging (TDI) has become more widely
used to assess left ventricular (LV) systolic and diastolic
function [10]. Parameters of diastolic function such as
early diastolic velocities measured as E prime (E'), the E'
to late diastolic filling (A') ratio (E'/A') and the transmitral
to mitral annular early diastolic velocity ratio (E/E') [11]
have all been shown to predict mortality and cardiovascu-
lar events [12]. The peak systolic velocity (S') is also a sen-
sitive marker for mild LV systolic impairment, even in
patients with a normal LV systolic function [13].
Methods
Hypercholesterolemic Rabbit Model
Twenty-seven adult male New Zealand White rabbits were
studied, 7 were fed normal rabbit chow (group 1) and the
remaining 20 were fed a high cholesterol diet as previous
described [14,15] for 6 months. Briefly, rabbits were fed a
high cholesterol diet (1%, Harlan-Sprague Dawley, Inc,
Indianapolis, IN) alternating with normal chow on a
monthly basis, 10 were treated with ezetimibe (1 mg/kg/
day) (group 2) throughout the 6 months and the remain-
ing were not (group 3). All studies were performed with
the approval of Michigan State University Animal Care
and Use Committee on Animal Investigations following
NIH guidelines.
Echocardiographic Images
After 6 months echocardiographic images were obtained
after inducing general anesthesia with ketamine (15 - 25
mg/kg) and xylazine (3 - 5 mg/kg). Food was withheld
overnight and the rabbits were placed in prone position
without restraint.
All images were obtained with a 7 MHz probe (Vivid 7/
Vingmed General Electric, Milwaukee, WI). Parasternal
and apical views were obtained with the probe positioned
at a cranial angle over a shaved area on the lower portion
of the thoracic wall as previously reported [16,17]. The
exact position of the transducer was adjusted as necessary
to acquire standard images. Echocardiographic measure-
ments by both 2D and M-mode were obtained in the par-
asternal long axis view. These included septal and
posterior left ventricular (LV) wall thickness, LV cavity size
(end-diastolic (LVEDD) and end-systolic (LVESD) dimen-
sions), aortic root, and left atrial anteroposterior diame-
ter. Fractional shortening was computed as follows:
[(LVEDD-LVESD)/LVEDD] × 100 and as global systolic
function was balanced the ejection fraction was calculated
with the Teicholz formula [18].
Doppler imaging of the mitral valve was obtained from
the apical four-chamber view. The following measure-
ments were obtained at the mitral inflow velocity image:
peak E and peak A wave velocities, E/A ratio, E wave accel-
eration and deceleration times, and isovolumetric relaxa-
tion time.
TDI was performed from an apical four-chamber view
with very low contrast and a 5 mm tissue sampling vol-
ume at the mitral annulus from both septal and lateral
walls. From the acquired images, the following diastolic
function parameters were measured: E', A', E'/A' and E/E'
wave ratio; the systolic parameter measured was S'.
All the measurements were obtained at the time of exam-
ination by the echosonographer and subsequently read by
two separate physicians who were blinded to the groups,




Blood samples were drawn from ear veins with a 25-gauge
needle and syringe at baseline and 3 months into the pro-
tocol. The samples were evaluated for cholesterol content
using a cholesterol kit (Thermo Electron Corporation,
Louisville, CO) according to the manufacturer's instruc-
tion.
Myocardial tissue
All rabbits were euthanized at six months (Euthonasol 1
cc IV) and the hearts removed. Blood was washed out of
the cavity and a segment of myocardial tissue (10 × 3 mm)
from the LV free wall was excised. Cholesterol levels were
measured in the tissue segment using a cholesterol Kit
(EnzyChrom Cholesterol Assay Kit (ECCH-100) BioAssay
Systems, Hayward, CA).Cardiovascular Ultrasound 2009, 7:56 http://www.cardiovascularultrasound.com/content/7/1/56
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Statistical Analysis
GraphPad InStat 3.06 (GraphPad Software, San Diego,
CA, USA) was used for statistical analysis. One way
ANOVA was used to compare the E/A, E'/A', E/E', S', myo-
cardial and serum cholesterol levels for all three groups.
Pearson Correlation analysis was done between echocar-
diographic, TDI variables; and serum and myocardial cho-
lesterol levels. A two tailed P value of < 0.05 was noted to
have statistically significant value.
Results
Echocardiographic Findings
A full echocardiographic study was obtained in 24/27 rab-
bits (89%); TDI were not obtainable in three due to imag-
ing difficulties involving adequate image resolution at the
mitral annulus. The 2-D and M-mode measurements were
similar and consistent without significant differences
among all three groups and with the published data [17]
(Table 1), and there were no significant differences noted
between the independent measurements obtained by the
echosonographer and the blinded readers.
Several TDI derived parameters were significantly differ-
ent among the groups (Figures 1, 2). The E'/A' ratio meas-
ured in the septal wall was higher in group 1 (1.93 ± 0.42)
and group 2 (1.82 ± 0.22) compared to group 3 (1.26 ±
0.62) (p = 0.03). Similar values and statistical differences
were noted for the lateral wall for group 1 (2.16 ± 0.5) and









Weight (kg) 2.59 3.1 ± 0.26 3.11 ± 0.16 3.05 ± 0.2
E/A * 2.19 1.80 ± 0.51 1.92 ± 0.37 1.55 ± 0.49
E'/A'‡ NA 1.93 ± 0.42 1.82 ± 0.22 1.26 ± 0.62
S'‡ NA 6.42 ± 2.55 6.55 ± 1.66 4.6 ± 0.69
E/E' NA 8.91 ± 1.54 8.48 ± 2.15 11.72 ± 5.33
E wave (cm/s) 59 60.6 ± 9.9 59.1 ± 8.5 58.0 ± 9.2
E dec (sec) NA 87.8 ± 22.5 93.4 ± 18.5 102.1 ± 22.1
IVSd (mm) 2.03 2.85 ± 0.37 2.87 ± 0.35 3.11 ± 0.60
IVSs (mm) 3.05 4.14 ± 0.69 4.25 ± 0.70 3.88 ± 0.33
LVIDd (mm) 14.37 15.14 ± 0.69 14.62 ± 2.38 14.77 ± 2.16
LVIDs (mm) 10.05 10.14 ± 0.37 10.5 ± 2.07 10.77 ± 1.85
LVFWd (mm) 2.16 3 ± 0.0 2.5 ± 0.75 2.66 ± 0.5
LVFWs (mm) 3.48 4.14 ± 0.89 3.62 ± 0.51 3.77 ± 0.66
FS (%) 30.13 30.85 ± 3.5 28.37 ± 6.36 28.22 ± 4.76
EF (%) 61.29 62.28 ± 5.02 58.37 ± 9.7 58.44 ± 7.76
Ao (mm) 8.26 9.42 ± 0.78 9.25 ± 1.48 9.33 ± 0.86
LA (mm) 9.66 8.85 ± 1.06 8.5 ± 1.41 9.33 ± 2.64
E wave = Peak E velocity, E dec = E wave decelation time IVSd = Intraventricular septum diastole, IVSs = Intraventricular septum systole, LVIDd = 
Left ventricular internal dimension diastole, LVIDs = Left ventricular internal dimension systole, LVFWd = Left ventricular free wall diastole, LVFWs 
= Left ventricular free wall systole, FS = Fractional shortening, EF = Ejection fraction, Ao = Aortic root diameter, LA = Left atrial diameter.
From: Fontes-Sousa, et al. M-mode and Doppler echocardiographic reference values for male New Zealand white rabbits. AJVR 2006;67:1725-1729 
(17).
* =p < 0.05 for group 1 vs. group 3
‡ =p < 0.05 for group 1 and group 2 vs. group 3Cardiovascular Ultrasound 2009, 7:56 http://www.cardiovascularultrasound.com/content/7/1/56
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group 2 (2.25 ± 0.8) compared to group 3 (1.38 ± 0.66; p
= 0.02) (Figure 3). However, the mitral Doppler inflow
velocity showed no difference with regards to E wave
acceleration or deceleration. Also, there was a borderline
significant decrease in the E/A ratio in group 3 when com-
pared to groups 2 and 1 respectively (1.55 ± 0.49 vs. 1.92
± 0.37 and 1.80 ± 0.51; p = 0.07 and p > 0.1; student t-
test).
Group 1 and group 2 had higher S' measurements com-
pared to group 3 respectively (6.42 ± 2.5 and 6.55 ± 1.66
vs. 4.6 ± 0.69; p = 0.03). Also, Group 3 was noted to have
an elevated E/E' ratio (11.5 ± 4.9) in comparison to both
group 2 (8.72 ± 2.0) and group 1 (8.91 ± 1.54) with a
trend towards statistical significance (respectively p =
0.07; p = 0.08; student t-test).
Serum and Tissue Cholesterol
Peak serum cholesterol levels were 495 ± 305 mg/dl vs.
114 ± 95 mg/dl and 87 ± 37 mg/dl; p < 0.01. Myocardial
cholesterol content was also significantly greater in group
3 vs. group 2 (0.105 ± 0.04 mg/g vs. 0.068 ± 0.02; p =
0.05; one tailed student t-test).
Correlation Between Echocardiography and Cholesterol 
Levels
There was a significant negative correlation between
serum cholesterol levels and the TDI derived measure-
ments including E' (r2 = 0.28, p = 0.009), S' (r2 = 0.16, p =
0.04), E'/A' (r2 = 0.37, p = 0.001) with a positive correla-
tion with E/E' (r2 = 0.24, p = -0.01). Also, there was a sig-
nificant negative correlation between myocardial
cholesterol content and E' (r2 = 0.16 p = 0.04) and S' (r2 =
0.15, p = 0.05) with a positive correlation with E/E' (r2 =
0.41, p < 0.01). However, there was no correlation
between serum or myocardial cholesterol levels and the E
wave peak velocity, the peak A wave velocity, E/A ratio or
ejection fraction (Table 2).
Discussion
This study showed a statistically significant in vivo correla-
tion between myocardial cholesterol loading and myocar-
dial dysfunction as measured via advanced
echocardiographic imaging but not via traditional
echocardiographic parameters. Prior studies on lipid low-
ering in the myocardium have primarily evaluated the
effects of triglycerides, but only a few have considered the
effects of cholesterol on myocardial function [19]. The
toxic effects of cholesterol on the myocardium have been
investigated by various methods and have been described
as "lipotoxic cardiomyopathy" [20], "cholesterol cardio-
myopathy" [19] and "cardiac steatosis" [21]. The data pre-
sented suggest that cholesterol accumulates in the
myocardium and affects both systolic and diastolic func-
tion; this was inhibited by reducing cholesterol absorp-
tion.
Zaca et al evaluated the role of cholesterol accumulation
in the myocardium of a dog model by using hemody-
namic measurements [22]. Also, Huang et al, Chiu et al
and Wu et al have all performed ex-vivo physiologic studies
of myocardial lipid content by histology and molecular
Tissue Doppler images from the septal wall of the ventricle Figure 1
Tissue Doppler images from the septal wall of the ventricle. Tissue Doppler images (bottom) obtained from the Septal 
wall (top) in two different rabbits on hypercholesterolemic diet with (right) and without ezetimibe (left). E' = peak early diasto-
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analysis [19,20,23]. Huang used a very similar model of
hypercholesterolemia in rabbits and demonstrated systo-
lic and diastolic dysfunction with individual myocytes in
a perfusion chamber and associated this finding with
reduced levels of sarcoplasmic/endoplasmic reticulum
Ca2_-ATPase (SERCA)-2 mRNA; we confirmed their
bench-top findings with TDI. Chiu and Wu on the other
hand used genetically modified mice models to obtain
very high cholesterol levels and they also found myocar-
dial dysfunction in their respective ex-vivo models. In our
study, we were able to confirm similar findings of myocar-
dial dysfunction via a non-invasive method in live sub-
jects.
Human studies demonstrating cardiac lipid accumulation
have been technically limited [24]. A recent human study
found myocardial triglyceride accumulation and impaired
diastolic function via magnetic resonance spectroscopy
[21]. However, in that study data was not obtainable in
over 25% of the subjects because of technical limitations.
In our study, as well as human studies, the image quality
with echocardiography is consistent and readily obtaina-
ble. Moreover, most studies [21,25] evaluated triglyceride,
rather than cholesterol levels and focused on the potential
alterations in myocardial metabolism.
The use of statins for congestive heart failure has yielded
conflicting results [25] with some studies demonstrating
improved LV function [26], symptomatology, clinical out-
comes [27] and mortality [28]. However, most studies
have tackled this problem at advanced stages of heart fail-
ure, but we demonstrated that measurable differences can
occur at the very earlier stages of LV dysfunction.
In our study, we lowered cholesterol with ezetimibe since
it has no known pleiotropic effects other than decreasing
cholesterol absorption [29]. This decrease was associated
with similar cholesterol levels as the chow fed group and
hence similar myocardial function measurements. Thus,
we were able to establish correlations between serum and
myocardial cholesterol levels and TDI markers of myocar-
dial function. This supports our hypothesis of a potential
role of cholesterol infiltration of the myocardium in the
pathogenesis of cardiac dysfunction. Thus, TDI measure-
Table 2: Correlations (r2) between TDI, 2D and Doppler echocardiographic parameters with serum and myocardial cholesterol
TDI parameters 2D and Doppler parameters
E'/A' E' S' E/E' E wave (cm/s) E/A EF (%)
Serum Cholesterol 0.37* 0.28* 0.17* 0.24* 0.01 0.004 0.004
Myocardial Cholesterol 0.008 0.16* 0.15* 0.41* 0.02 -0.01 0.004
*=p < 0.05
Tissue Doppler image from the lateral wall of the ventricle Figure 2
Tissue Doppler image from the lateral wall of the 
ventricle. Tissue Doppler image (bottom) obtained from 
the lateral wall of the ventricle (top) in a control rabbit. E' = 
peak early diastolic velocity, A' = peak atrial velocity, S' = 
peak systolic velocity.
Myocardial Function by Subgroups Figure 3
Myocardial Function by Subgroups. E'/A' (septal wall), 
E'/A' lat (lateral wall) and S' measurements in hypercholester-
olemic rabbits with and without ezetimibe and control rab-
bits. *p < 0.05 for group without ezetimibe vs. with ezetimibe 
and control.Cardiovascular Ultrasound 2009, 7:56 http://www.cardiovascularultrasound.com/content/7/1/56
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ments may be used as a marker of cardiac cholesterol infil-
tration in metabolic diseases such as diabetes,
hypercholesterolemia and metabolic syndrome.
Potential Mechanisms
The mechanism by which hypercholesterolemia alters
myocardial function is not clear, and it may overlap with
its established effects on the coronary macro and microv-
asculature (A). Other studies have demonstrated the dele-
terious effect of high glucose levels on myocardial
function with microvascular dysfunction and progressive
LV remodeling being implicated for such changes [30]. It
has been suggested that the deposition of cholesterol in
the myocardium may cause a cholesterol myopathy simi-
lar to other infiltrating diseases [31]. Alternatively, myo-
cardial metabolism may shift ATP production from a
glucose based to a free fatty acid state [32] and flood the
Krebs cycle to create more free radicals that injure the
myocardium [33,34].
Limitations
This study does not establish causality between higher
cholesterol and myocardial function. We used an aggres-
sive dietary regimen to attempt to produce effects that
may otherwise take years to develop in humans. Extrapo-
lating these findings to the clinical arena may be relevant
based on a lone study that found similarities between cho-
lesterol accumulation in lipotoxic rat hearts to human
transplanted hearts [35].
Conclusion
A high cholesterol diet is associated with decrease in both
systolic and diastolic cardiac function in rabbits as meas-
ured by TDI, while ezetimibe is protective by its capacity
to decrease cholesterol absorption. The mechanism by
which cholesterol alters the myocardial function remains
to be established by further research possibly with imag-
ing and biochemical studies of the myocardium.
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